Carisma Therapeutics, Inc. (CARM)
Fuera de horario:
Carisma Therapeutics, Inc.
3675 Market Street
Suite 200
Philadelphia, PA 19104
United States
267-491-6422
https://www.carismatx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 107
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Steven Kelly | President, CEO & Director | 786.91k | N/D | 1965 |
| Mr. Michael Klichinsky Ph.D., Pharm.D., PharmD | Co-Founder & Chief Scientific Officer | 525.43k | N/D | 1990 |
| Mr. Richard S. Morris CPA | CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off. | 584.85k | N/D | 1974 |
| Dr. Saar Gill M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | N/D | N/D | N/D |
| Dr. Daniel J. Cushing FCP, Ph.D. | Chief Technology & Development Officer | N/D | N/D | N/D |
| Mr. Eric H. Siegel J.D., MBA | General Counsel & Corporate Secretary | N/D | N/D | 1965 |
| Ms. Terry Shields | Senior Vice President of Human Resources | N/D | N/D | N/D |
| Mr. Tom Wilton | Chief Business Officer | N/D | N/D | 1974 |
Descripción
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Gestión corporativa
La calificación ISS Governance QuickScore de Carisma Therapeutics, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 10; Junta: 7; Derechos del accionista: 7; Compensación: 8.
